Levetiracetam for Hemorrhagic Brain Contusion
Routine prophylactic levetiracetam should not be used for hemorrhagic brain contusion, as current evidence does not support its efficacy in preventing post-traumatic seizures and may worsen functional outcomes, though it can be considered in select high-risk cases where levetiracetam is preferred over phenytoin due to better tolerability. 1
Primary Recommendation: Against Routine Prophylaxis
The 2018 Anaesthesia guidelines explicitly state that prevention of post-traumatic seizures with antiepileptic drugs (AEDs) cannot be recommended based on comprehensive review of 11 clinical trials. 1 This recommendation is supported by:
- No significant effect of AEDs on preventing early or delayed post-traumatic seizures across multiple studies 1
- Evidence of worsening neurological outcomes with AEDs in some studies 1
- The 2024 Neurocritical Care Society guidelines similarly suggest that ASM or no ASM may be used (weak recommendation, low quality evidence), indicating equipoise 2
When Prophylaxis May Be Considered
If prophylaxis is deemed necessary due to specific risk factors, levetiracetam should be preferred over phenytoin/fosphenytoin due to superior tolerability. 1
Risk factors that may warrant consideration include:
- Brain contusion (the specific scenario in question) 1
- Acute subdural hematoma 1
- Skull fracture 1
- Loss of consciousness or amnesia >24 hours 1
- Age >65 years 1
- Prior history of epilepsy 1
- Craniectomy 1
Dosing Strategy (If Used)
Standard Dosing Approach:
Start with levetiracetam 1000 mg IV/PO every 12 hours (500 mg BID). 3 However, emerging evidence suggests this may be inadequate:
Evidence for Higher Dosing:
- Standard 500 mg BID dosing achieves subtherapeutic levels in most critically ill TBI patients 4, 5, 6
- A 2024 prospective study found that higher doses (750-1000 mg BID) were 2.23 times more likely to achieve target levels (12-46 μg/mL) and reduced seizure odds by 68% compared to 500 mg BID 4
- Neurocritically ill patients exhibit rapid levetiracetam clearance with elimination half-life of only 4.8 hours (versus 6-8 hours in healthy adults) 5
- Augmented renal clearance (ARC) occurs in 77% of severe TBI patients, resulting in significantly lower drug concentrations 6
Optimal Dosing Recommendations:
Consider levetiracetam 1000 mg every 8 hours or 2000 mg every 12 hours for patients with severe TBI to achieve therapeutic levels. 5 Monte Carlo simulations support regimens of 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours for optimal target attainment. 5
Weight-based consideration: Use 75 kg as a breakpoint—patients >75 kg may require higher doses. 5
Duration of Prophylaxis (If Used)
Limit prophylaxis to ≤7 days maximum. 2, 7 The evidence supporting short duration includes:
- No benefit for preventing late seizures (>7 days) with prolonged use 1
- Cognitive outcomes and adverse events appear worse with protracted use 2
- The 2024 Neurocritical Care Society guidelines recommend short duration (≤7 days) if prophylaxis is used 2
Important Caveats
Lack of Efficacy Evidence:
- No antiepileptic drug has demonstrated clear efficacy in preventing post-traumatic seizures in well-designed trials 1
- A 2022 meta-analysis found no significant reduction in seizure incidence with levetiracetam prophylaxis versus no medication in TBI patients 8
Potential Harms:
- Increased adverse events reported with prophylactic ASM use 1, 7
- Some studies showed worsening neurological outcomes with AEDs 1
Dosing Challenges:
- 90% of levetiracetam studies used low, possibly subtherapeutic doses (250-500 mg BID), which may explain lack of demonstrated efficacy 8
- Only 54% of patients achieve target levels with standard dosing 4
- Underdosing is common in clinical practice 4, 9
Monitoring Considerations:
If prophylaxis is used, consider checking serum levetiracetam levels at steady state (after 2-3 days) to ensure therapeutic range of 12-46 μg/mL, particularly in patients with severe TBI or suspected ARC. 4, 5